In a new study entitled “Neuronal death induced by misfiled prion protein is due to NAD+ depletion and can be relieved in vitro and in vivo by NAD+ replenishment,” researchers report that in protein misfolding neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis, neuronal death…
Cell Metabolite Reduces Neuronal Death in ALS, Study Shows
In a new study entitled “Transcriptome profiling of expression changes during neuronal death by RNA-Seq,” a research team employed RNA-sequencing to identify novel genes that might help regulate the death of neurons, a characteristic of neurodegenerative diseases. The study was published in the journal…
The national nonprofit United Spinal Association is advocating along with the Washington DC Taxicab Commission (DCTC) for the implementation of the DC Taxicab Service Improvement Amendment Act of 2012’s regulations and an increase in taxis able to carry wheelchairs. The implementation of the rule may impact the lives of people suffering from…
Investigators at the Northwestern University Feinberg School of Medicine are currently enrolling participants for a clinical trial (ClinicalTrials.gov Identifier: NCT00821132), that aims to identify genes that increase risk for sporadic Amyotrophic Lateral Sclerosis (ALS) or cause inherited ALS. The study, entitled “Identification of Genes Causing Familial ALS or Increasing Risk…
BioMotiv is a drug advancement accelerator associated with The Harrington Project, the University of California San Francisco (UCSF), and University of Washington, Seattle working on breakthrough discoveries and new therapeutics that have the potential to address unmet clinical needs. Recently, the accelerator announced the creation of a platform company, OptiKira, that will…
The first app for amyotrophic lateral sclerosis (ALS) patients who have begun to lose their speaking abilities was recently launched by UK company Therapy Box. The app was designed to substitute standard text-to-speech synthesis with a synthesizer based on the patient’s own voice. The Predictable 4 app has entered the ModelTalker program, at a…
Dr. Nancy Bonini A recent editorial published in the journal Neurology highlights the existing scope of clinical knowledge concerning genetic susceptibility that makes individuals prone to developing amyotrophic lateral sclerosis (ALS). The editorial content was based on a thorough…
A research team from the University of Wisconsin-Madison Waisman Center led by Su Chun Zhang, established a simple model in mice to investigate the role of human astrocytes in neurologic diseases such as Amyotrophic Lateral Sclerosis (ALS), Rett Syndrome and Huntington’s disease. The study entitled…
Dual platform regenerative medicine company, Neuralstem, Inc., is wrapping up its participation in the 17th Annual BIO CEO & Investor Conference taking place February 9 to the 10th at the Waldorf Astoria in New York. President and CEO, Richard Garr, was invited to present…
Biopharmaceutical company Genervon recently reported observing improvements in a 46-year-old-man with advanced amyotrophic lateral sclerosis (ALS) taking the Company’s drug candidate GM604. The patient showed increased speech, swallowing and suction capabilities after a 12-week treatment. The drug, which has yet to be approved by the…
Recent Posts
- New book shares personal stories and insights from people living with ALS
- Developers expand collaboration to test 2 novel targets for ALS treatments
- Trial testing new ALS gene therapy starts dosing patients in Australia
- In life with ALS, we find moments of ‘genius’ to keep our minds active
- Brain imaging agent shows promise for detecting toxic ALS protein